News No US Remicade biosimilar until at least October Pfizer must wait until 180 day period ends, court fight ongoing.
Clinical Sandoz biosimilar trial hailed as 'landmark' Patients switched between the originator and the near-copy.
News Biosimilars don't need big market share to bring savings - I... Competition can also drive down price of entire drug class.
News US regulatory advisers to review Amgen's Humira biosimilar World's biggest selling drug could face competition.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
